Investor's Business Daily on MSN3h
Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'
Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock fell.
2BFLY : Butterfly Network Is 'Pioneering Digital Ultrasound Market,&#...
Butterfly Network exceeded Q4 estimates with 35% revenue growth. William Blair sees strong upside, citing homecare potential ...
Palantir Technologies (PLTR): Among the Best Reddit Stocks to Invest In
We recently published a list of 11 Best Reddit Stocks to Invest In. In this article, we are going to take a look at where ...
William Blair Upgrades DocuSign (DOCU) Stock on IAM Platform’s Potential
Software company DocuSign (DOCU) scored a rating upgrade from Hold to Buy from William Blair, thanks to the optimism about ...
Finbold8h
Analyst uprgades Palantir stock
A Wall Street analyst believes Palantir's (NASDAQ: PLTR) expanding artificial intelligence (AI) ecosystem, marked by major ...
William Blair Reaffirms Their Hold Rating on Science Applications (SAIC)
William Blair analyst Louie DiPalma maintained a Hold rating on Science Applications (SAIC – Research Report) today. The company’s shares ...
Possible boycott of US super fighter by closest ally: “It was the fighter we needed, but we are examining other alternatives”
Portugal has announced that it will not go ahead with the purchase of Lockheed Martin F-35 aircraft. Canada is also looking for alternatives to the powerful ...
William Blair Issues Negative Estimate for Duluth Earnings
Equities research analysts at William Blair cut their Q4 2026 earnings estimates for shares of Duluth in a research report issued to clients and investors on Thursday, March 13th. William Blair ...
What is William Blair’s Estimate for Sprinklr Q1 Earnings?
Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Sprinklr in a note issued ...